- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Interventions
- Sofosbuvir/velpatasvir (Epclusa®)
- Drug
- Lead sponsor
- Jennifer Havens
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Hazard, Kentucky
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 4,019
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
- Interventions
- sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,006 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 106
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- LY2940680, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Fayetteville, Arkansas • Athens, Georgia • Las Vegas, Nevada + 8 more
- Conditions
- Opioid-use Disorder
- Interventions
- PROUD Intervention
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 16 Years to 90 Years
- Enrollment
- 377,373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Miami, Florida • Detroit, Michigan • The Bronx, New York + 3 more
- Conditions
- Cognitive Change
- Interventions
- C1 - Standard Perceptual Learning (SPL), C2 - Long Training (LT), C3 - Short Staircases (SS), C4 - Mixed Difficulty (MD), C5 - Noise Training (NT), C6 - Training with Flankers (TWF), C7 - Parafoveal Training (PT), C8 - Stimulus Variety (SV), C8a - Complex Features (CF), C9 - Exogenous Attention Training (ExAT), C10 - Endogenous Attention Training (EnAT), C11 - Multisensory Facilitation (MF), No Contact Control
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Riverside, California • Boston, Massachusetts • Madison, Wisconsin
- Conditions
- Advanced Solid Tumor
- Interventions
- YL201, YL201 and atezolizumab
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
- Conditions
- Healthy Volunteers
- Interventions
- BGB-43395
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Skin Cancer
- Interventions
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Chronic Pain
- Interventions
- Intraoperative Parameter Testing, Proprioception Testing During Stimulation, Gait Analysis During Stimulation
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Kidney Transplant Rejection
- Interventions
- AlloSure
- Device
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- Fairfield, California • Fresno, California • Granada Hills, California + 15 more
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 4
- States / cities
- Manhasset, New York • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Pivekimab Sunirine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Atlanta, Georgia • Valhalla, New York + 2 more
- Conditions
- Graves' Disease, Graves Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 29
- States / cities
- Carlsbad, California • Orange, California • Pasadena, California + 24 more
- Conditions
- Neoplasms
- Interventions
- JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
- Drug
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 4
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- ONO-7018
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Kansas City, Missouri • Florham Park, New Jersey + 7 more
- Conditions
- Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 11
- States / cities
- La Jolla, California • Redlands, California • Whittier, California + 8 more
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
- Interventions
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
- Drug · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
- Conditions
- Glycemic Response, Breast Feeding, Exclusive, Eating Behavior
- Interventions
- Beef Diet Intervention, Impossible Beef Diet Intervention
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Disulfiram, Copper Gluconate, Surgery, Radiation, Temozolomide
- Drug · Procedure · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer's Disease
- Interventions
- Semorinemab, Placebo, [18F]GTP1
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 31
- States / cities
- Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more
- Conditions
- Healthy
- Interventions
- LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Amputation, Spina Bifida
- Interventions
- In-person wheelchair propulsion training program, 30-minute education session
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri